Covered recipient · General Payments record
TUAN HUY V TRAN
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$6,145.14
147 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,835.63 | 141 |
| Consulting Fee | $2,250.00 | 1 |
| Travel and Lodging | $1,038.16 | 2 |
| Education | $21.35 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Corcept Therapeutics | $3,708.26 | 9 |
| Novo Nordisk Inc | $526.31 | 30 |
| AstraZeneca Pharmaceuticals LP | $347.54 | 12 |
| Merck Sharp & Dohme Corporation | $207.82 | 16 |
| Dexcom, Inc. | $204.23 | 6 |
| SANOFI-AVENTIS U.S. LLC | $177.51 | 15 |
| Lilly USA, LLC | $165.57 | 12 |
| Abbott Laboratories | $138.86 | 12 |
| W. L. Gore & Associates, Inc. | $130.25 | 1 |
| Amgen Inc. | $109.52 | 7 |
| AbbVie, Inc. | $84.89 | 5 |
| Becton, Dickinson and Company | $47.67 | 3 |
| Medtronic MiniMed, Inc. | $43.24 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $38.90 | 2 |
| Shire North American Group Inc | $36.85 | 2 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.41 | 2 |
| Amarin Pharma Inc. | $25.06 | 2 |
| Alexion Pharmaceuticals, Inc. | $19.06 | 1 |
| PFIZER INC. | $17.23 | 1 |
| Radius Health, Inc. | $16.22 | 1 |
| Insulet Corporation | $15.35 | 1 |
| Ferring Pharmaceuticals Inc. | $15.27 | 1 |
| Amneal Pharmaceuticals LLC | $13.89 | 1 |
| Valeritas, Inc. | $12.05 | 1 |
| Janssen Pharmaceuticals, Inc | $11.18 | 1 |
Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TUAN HUY V TRAN
NPI 1750369161 · CMS profile ID 352285
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
METAIRIE, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1750369161?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TUAN HUY V TRAN, NPI 1750369161, CMS profile ID 352285. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750369161?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). TUAN HUY V TRAN, NPI 1750369161, CMS profile ID 352285. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750369161?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- TUAN HUY V TRAN, NPI 1750369161, CMS profile ID 352285, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1750369161?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
147 matching records · $6,145.14 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–147 of 147.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corporation | $2.94 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695422469 | CMS |
| SANOFI-AVENTIS U.S. LLC | $17.19 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694280985 | CMS |
| Medtronic MiniMed, Inc. | $13.32 | 04/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648789931 | CMS |
| AbbVie, Inc. | $19.65 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647862729 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.03 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700084417 | CMS |
| Novo Nordisk Inc | $14.64 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 669481251 | CMS |
| Abbott Laboratories | $6.86 | 03/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 664395843 | CMS |
| Merck Sharp & Dohme Corporation | $13.01 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695390335 | CMS |
| Lilly USA, LLC | $12.50 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658203519 | CMS |
| Dexcom, Inc. | $112.27 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688527521 | CMS |
| Merck Sharp & Dohme Corporation | $12.09 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695413401 | CMS |
| Novo Nordisk Inc | $18.05 | 03/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 669481249 | CMS |
| Novo Nordisk Inc | $14.00 | 03/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 669481253 | CMS |
| SANOFI-AVENTIS U.S. LLC | $4.64 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693953653 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.95 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685375153 | CMS |
| AstraZeneca Pharmaceuticals LP | $46.09 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685863761 | CMS |
| AbbVie, Inc. | $18.12 | 02/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647862731 | CMS |
| Corcept Therapeutics | $2,250.00 | 02/23/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695521387 | CMS |
| Corcept Therapeutics | $61.20 | 02/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695521393 | CMS |
| Corcept Therapeutics | $5.69 | 02/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695521403 | CMS |
| Corcept Therapeutics | $230.36 | 02/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695521417 | CMS |
| Corcept Therapeutics | $976.96 | 02/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695521425 | CMS |
| Corcept Therapeutics | $131.74 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695521407 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.41 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685658519 | CMS |
| AstraZeneca Pharmaceuticals LP | $6.00 | 02/21/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685865979 | CMS |
| Insulet Corporation | $15.35 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705036961 | CMS |
| Novo Nordisk Inc | $13.00 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 668799759 | CMS |
| Amarin Pharma Inc. | $12.78 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699080917 | CMS |
| Merck Sharp & Dohme Corporation | $13.51 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695284909 | CMS |
| Abbott Laboratories | $19.29 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 664391615 | CMS |
| Becton, Dickinson and Company | $20.24 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703302703 | CMS |
| Merck Sharp & Dohme Corporation | $15.55 | 02/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695264513 | CMS |
| Amgen Inc. | $11.40 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663142679 | CMS |
| AstraZeneca Pharmaceuticals LP | $119.04 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685219083 | CMS |
| Novo Nordisk Inc | $21.64 | 02/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 668799831 | CMS |
| Merck Sharp & Dohme Corporation | $12.49 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695306463 | CMS |
| SANOFI-AVENTIS U.S. LLC | $7.00 | 01/24/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693893039 | CMS |
| Lilly USA, LLC | $13.82 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658207915 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.87 | 01/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700084419 | CMS |
| Merck Sharp & Dohme Corporation | $15.38 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695215433 | CMS |
| AbbVie, Inc. | $16.40 | 01/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647862727 | CMS |
| Dexcom, Inc. | $14.74 | 01/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688527527 | CMS |
| Novo Nordisk Inc | $16.51 | 01/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 668799793 | CMS |
| Novo Nordisk Inc | $3.75 | 01/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682912307 | CMS |
| Lilly USA, LLC | $13.74 | 01/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658207913 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.15 | 01/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685104173 | CMS |
| Dexcom, Inc. | $10.93 | 01/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688527531 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $345,318.89 | 47 |
| PY2024 | Principal investigator | $330,947.66 | 35 |
| PY2023 | Principal investigator | $356,190.10 | 25 |
| PY2022 | Principal investigator | $236,380.90 | 21 |
| PY2021 | Principal investigator | $282,458.50 | 109 |
| PY2020 | Principal investigator | $307,425.92 | 96 |
| PY2019 | Principal investigator | $83,728.00 | 36 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
47 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,520.00 | 12/31/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH LLC | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202535091 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,433.00 | 12/18/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225415052 |
| Principal investigator 1 | ABBVIE INC. | $4,652.10 | 12/05/2025 | Non-covered Recipient Entity DBA OMEGA CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202529214 |
| Principal investigator 1 | ABBVIE INC. | $8,935.65 | 11/05/2025 | Non-covered Recipient Entity DBA OMEGA CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202522997 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,730.00 | 10/23/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225414114 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,400.78 | 10/16/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190312057 |
| Principal investigator 1 | ABBVIE INC. | $12,282.30 | 10/09/2025 | Non-covered Recipient Entity DBA OMEGA CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202514839 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22,000.00 | 09/24/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190307067 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,553.00 | 09/22/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190312059 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,178.00 | 09/18/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225414812 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,050.00 | 09/10/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure | No dispute reported | 06/30/2026 | 1185555125 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $454.28 | 09/08/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190311387 |
| Principal investigator 1 | ABBVIE INC. | $6,054.75 | 09/04/2025 | Non-covered Recipient Entity DBA OMEGA CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202508542 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $5,631.00 | 08/29/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic | No dispute reported | 06/30/2026 | 1225408556 |
| Principal investigator 1 | ABBVIE INC. | $9,396.00 | 08/06/2025 | Non-covered Recipient Entity DBA OMEGA CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202503471 |
| Principal investigator 1 | ABBVIE INC. | $383.09 | 07/10/2025 | Non-covered Recipient Entity DBA OMEGA CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202497806 |
| Principal investigator 1 | ABBVIE INC. | $8,726.40 | 07/02/2025 | Non-covered Recipient Entity DBA OMEGA CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202494411 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,376.29 | 06/30/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190307057 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $14,000.00 | 06/24/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C | No dispute reported | 06/30/2026 | 1190311385 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,239.00 | 06/19/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225412422 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $19,593.00 | 06/05/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225412382 |
| Principal investigator 1 | ABBVIE INC. | $10,609.65 | 06/03/2025 | Non-covered Recipient Entity DBA OMEGA CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202488157 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,627.74 | 05/21/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C | No dispute reported | 06/30/2026 | 1190307063 |
| Principal investigator 1 | ABBVIE INC. | $10,162.80 | 05/07/2025 | Non-covered Recipient Entity DBA OMEGA CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202483857 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $794.50 | 05/01/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C | No dispute reported | 06/30/2026 | 1190307065 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $110.00 | 04/30/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225406640 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,849.00 | 04/28/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225403695 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $280.61 | 04/23/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190307061 |
| Principal investigator 1 | ABBVIE INC. | $3,896.10 | 04/03/2025 | Non-covered Recipient Entity DBA OMEGA CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202472500 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $14,843.27 | 03/31/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190307055 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $6,299.00 | 03/27/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225403241 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $246.07 | 03/19/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes | No dispute reported | 06/30/2026 | 1225404529 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,440.00 | 03/19/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes | No dispute reported | 06/30/2026 | 1225405120 |
| Principal investigator 1 | ABBVIE INC. | $1,393.20 | 03/07/2025 | Non-covered Recipient Entity DBA OMEGA CLINICAL RESEARCH LLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202460689 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,715.00 | 02/27/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190311373 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $11,926.17 | 02/27/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190311377 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,006.00 | 02/19/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes | No dispute reported | 06/30/2026 | 1225403931 |
| Principal investigator 1 | ABBVIE INC. | $2,454.30 | 02/06/2025 | Non-covered Recipient Entity DBA OMEGA CLINICAL RESEARCH LLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202448387 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $8,650.52 | 02/04/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190311383 |
| Principal investigator 1 | Eli Lilly and Company | $330.00 | 01/31/2025 | Non-covered Recipient Entity DIABETES AND METABOLISM ASSOCIATES, APMC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VOLENRELAXIN IN ADULTS WITH CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187879945 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $18,707.61 | 01/28/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190311379 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $17,109.06 | 01/27/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190311375 |
| Principal investigator 1 | Eli Lilly and Company | $23,683.00 | 01/21/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH LLC DBA TUAN HUY TRAN | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VOLENRELAXIN IN ADULTS WITH CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187890516 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,531.80 | 01/17/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | a randomised,double blind,placebo controlled study to evaluate cortisol reserve in response to adrenocorticotropic hormone stimulation test following treatment with baxdrostat for eight weeks in participants with ucontrolled hypertension | No dispute reported | 06/30/2026 | 1185555123 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,434.00 | 01/17/2025 | Non-covered Recipient Entity Omega Clinical Research Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic | No dispute reported | 06/30/2026 | 1225411824 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,717.71 | 01/15/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190307059 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $913.14 | 01/08/2025 | Non-covered Recipient Entity OMEGA CLINICAL RESEARCH | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190311381 |